Elizabeth J. PhillipsChonlaphat SukasemMichelle Whirl-CarrilloDaniel J. MüllerHenry M. DunnenbergerWasun ChantratitaBarry GoldspielYuan Tsong ChenBruce C. CarletonAlfred L. GeorgeTaisei MushirodaTeri KleinRoseann S. GammalMunir PirmohamedDuke University Medical CenterNorthShore University HealthSystemVanderbilt University Medical CenterUniversity of LiverpoolSt. Jude Children's Research HospitalAcademia Sinica TaiwanUniversity of TorontoRikenNIH Clinical CenterFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityCentre for Addiction and Mental HealthNorthwestern University Feinberg School of MedicineStanford UniversityThe University of British ColumbiaMCPHS University2019-08-282019-08-282018-04-01Clinical Pharmacology and Therapeutics. Vol.103, No.4 (2018), 574-58115326535000992362-s2.0-85041319988https://repository.li.mahidol.ac.th/handle/20.500.14594/46818© 2018 American Society for Clinical Pharmacology and Therapeutics The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1002/cpt.1004